Clinical trialNACompleted
Proton Radiotherapy for Upper Gastrointestinal Malignancies
A Feasibility and Registration Study of Proton Radiotherapy for Upper Gastrointestinal Malignancies
- Outcome
- Outcome unknown
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- August 2011
- Expected end
- December 2019
- Enrollment
- 22 participants
- Sites
- 1
- Primary outcomes
- Serious Adverse Events; Acute Toxicity
- Sponsor
- Other
- Results posted
- 2019-11-04
- Last update
- 15 April 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The primary objectives are to determine feasibility and the acute toxicity profile of proton therapy with concurrent continuous infusion 5-FU chemotherapy. Secondary objectives are to determine late toxicities and to generate preliminary data on clinical efficacy.
Detailed description public domain (ClinicalTrials.gov)
This protocol invites patients with cancer of the upper digestive tract who will receive simultaneous proton radiation therapy and chemotherapy. The purpose of this study is to use a newer form of radiation therapy called proton radiation and to determine if its use is safe and effective in people with this type of cancer. Doctors will assess the safety of this method of treatment, record the side effects participants experience while receiving the standard dose of proton radiation.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Serious Adverse Events [90 days]. Count Of Participants, Participants. Proton RT (n=22): 0.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Acute Toxicity [90 days]. Count Of Participants, Participants. Proton RT (n=22): 14.